Skip to main content
. 2014 Sep 23;42(18):11589–11600. doi: 10.1093/nar/gku860

Figure 4.

Figure 4.

Promoter-wide location analysis identifies targets of NME2 involved in metastatic progression. (A) ChIP-chip for NME2 across promoters of human genome: representative binding sites (peaks) and enrichment score on chromosome 8 in UCSC browser format. (B) Overlap of ChIP-chip and expression microarray results identified genes with change in mRNA level as well as binding of NME2 to their respective promoters as direct targets of NME2. (C) Position of NME2 binding site with respect to TSS and ChIP-chip enrichment score within the 64 direct targets of NME2 (left panel) and the relative change (log ratio) in expression of the transcript as determined by microarrays on targeted depletion of NME2 in A549 cells (right panel). (D) NME2-direct targets (36 probes representing 27 genes) show changes in expression across 93 lung carcinoma transcriptomes (grouped stage-wise) concordant with changes in gene expression profile obtained in A549 cells; P = 0.003 (left panel); correlation of relative fold change in expression in clinical samples versus NME2-depleted A549 cells (P < 0.0001 for correlation coefficient) (right panel).